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Viscoelastic methods (VEM) made available the bedside assessment of blood clotting.
Unlike standard laboratory tests, the results are based on the whole blood coagulation
and are available in real time at a much faster turnaround time. In combination with our
new knowledge about pathophysiology of the trauma-induced coagulopathy, the goal-
oriented treatment protocols have been recently proposed for the initial management of
bleeding in trauma victims. Additionally, the utility of viscoelastic monitoring devices has
been proved even outside this setting in cardiosurgical patients or those undergoing liver
transplantation. Many other situations were described in literature showing the potential
use of bedside analysis of coagulation for the management of bleeding or critically ill
patients. In the near future, we may expect further improvement in current bedside
diagnostic tools enabling not only the assessment of secondary hemostasis but also the
platelet aggregation. More sensitive assays for new anticoagulants are underway. Aim of
this review is to offer the reader a multidisciplinary overview of VEM and their potential
use in anesthesiology and critical care.
Keywords: coagulation, viscoelastic methods, point-of-care testing, trauma-induced coagulopathy, transfusion,
thrombosis
Introduction
In the contemporary emergency, intensive care medicine and anesthesia time are regarded as one
of the most important factors affecting the patients’ outcome. Timely administration of antibiotics
affects septic patients’ survival; prompt volume and/or catecholamine resuscitation have been
repeatedly associated with better outcomes in many different critical states. On the other hand,
individualization and goal-oriented treatments also seem to offer this advantage. In order to be
able to tailor the treatment to patients’ individual needs, the information describing the actual
state is paramount. Because the nature of acute critical illness is often changing in very rapid pace,
many contemporary diagnostic tools are too slow and hence inappropriate to combine these two
approaches of timely administered but goal-oriented treatments. For this reason, several point-of-
care testing (POCT) devices were introduced into the clinical praxis in the last few years or decades.
Unlike others (hemoglobin or blood glucose bedside analyzers), the POCT as a tool for assessing
blood clotting has been disregarded for quite a long time. The history of viscoelasticmethods (VEM)
Abbreviations: ATC, acute trauma coagulopathy; POCT, point-of-care testing; TIC, trauma-induced coagulopathy; VEM,
viscoelastic methods.
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has started already in the beginning of twentieth century, and the
first prototype of thromboelastography (TEG) was introduced in
1948 by Harter (1). Nevertheless, the analysis of activated clotting
time with the use of Hemochron or similar devices in patients
on heparin anticoagulation was for a long time the only widely
applied clotting POCT in clinical praxis. The paradigm shift
based on the new knowledge about massive bleeding and trauma-
associated coagulopathies observed in the late 1990s and in the
beginning of twenty-first century marked the increased interest
in VEM. Nowadays, the TEG/thromboelastometry seems to be a
very important and rapidly developing field of acute medicine.
Its ability to help to distinguish the most important coagulation
deficiencies makes it increasingly interesting in the goal-oriented
coagulation management of massive bleeding. Especially in view
of the fact that standard laboratory coagulation assays (thrombin
and prothrombin time and activated partial thromboplastin time)
have been shown as insufficient to correlate with the bleeding in
acute trauma setting (2). Also, the turnaround times of standard
tests were demonstrated to be about 45min in comparison with
10min when using the first applicable VEM-derived variables (3,
4). Besides the initial management of bleeding in traumatized or
operated patients, the evidence starts to accumulate the fact that
VEM could also offer important information in the later course
of critical illness to diagnose and manage the hypercoagulative
phenotype (5).
Widely Available Methods of VEM
In the contemporary praxis, two devices are mostly used: the
older TEG® device (Haemoscope Corporation, Niles, IL, USA)
and newer ROTEM® (Pentapharm GmbH, Munich, Germany) –
see Figure 1. Third device, namely the Sonoclot Analyzer (Sienco
Inc., Arvada, CO, USA), is also available, whereas there is much
less evidence for the use of this third device in clinical praxis than
the previous ones. Principles of all the VEM devices are based
on the measurement of change in viscoelastic properties of the
whole blood during the clot formation. The firmer the clot, the
higher is the force opposing the movement of rotating (TEG®
and ROTEM®) or vibrating (Sonoclot) particles of the measuring
device. Unlike laboratorymethods of blood coagulation, the VEM
devices are not only able to assess the time needed to form fibrin
polymers, but they also allow the monitoring of further clot for-
mation, its strength, and in some cases the potential lysis as well.
The use of the whole blood enables to evaluate the influence of
blood cellular components and their phospholipid surfaces on clot
formation and its final strength. The tests are mostly performed
in heated cup that allows the clot formation assessment under
the real conditions of patients’ body temperature. The detailed
methodology of all three devices is given in multiple published
papers (6, 7).
In routine praxis, several clotting activators and cofactors are
used to evaluate different coagulation pathways. Both TEG®
and ROTEM® influencing each other’s development offer similar
assays (Table 1). Even though similarities in parameters offered
by these methods can be found, the numerical values are not
directly interchangeable due to differentmethods of assessment of
viscoelastic forces and time-wise definition of variables (Table 2;
Figure 2). Additionally, these widely used variables and also other
derived or calculated parameters are displayed in the devices,
and some new variables are under development (8). In a similar
method, several specific assays are described in the literature fur-
ther broadening the analytical possibilities of this method (9, 10).
VEM in Acute Trauma Care
Till now, TIC was believed to be caused by the consumption
of coagulation factors in conjunction with the so-called lethal
triad (hypothermia, acidosis, and dilution). In order to reverse
A B
FIGURE 1 | The most commonly used viscoelastic devices – the ROTEM® device (A) and the TEG® device (B).
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TABLE 1 | List of commercially available tests for ROTEM® and TEG® devices.
Test Activator Description
ROTEM® TESTS
NATEM None Clot analysis of native blood
EXTEM Tissue factor Test of “extrinsic pathway” – fastest clot analysis; usable in comparison with APTEM and FIBTEM
INTEM Contact activator Test of “intrinsic pathway”; usable in comparison with HEPTEM
FIBTEM Tissue factor+ cytochalasin D Test of fibrin net polymerization after platelet inhibition (in comparison with EXTEM)
APTEM Tissue factor+ aprotinin Test of fibrinolysis (in comparison with EXTEM)
HEPTEM Contact activator+ heparinase Test of residual heparinization (in comparison with INTEM)
TEG® TESTS
Na-TEG None Clot analysis of native blood
RapidTEG Kaolin+ tissue factor Test of both “intrinsic and extrinsic pathways”
Kaolin TEG Kaolin Test of “intrinsic pathway”
Kaolin TEG with heparinase Kaolin+ heparinase Test of residual heparinization (in comparison with Kaolin TEG)
Functional fibrinogen Kaolin+GpIIb/IIIa inhibition Test of fibrin net polymerization after platelet inhibition (in comparison with Kaolin TEG)
TABLE 2 | List and comparison of the most important variables describing
the VEM-derived curve.
Variable ROTEM® TEG®
Clotting time
(2mm amplitude)
CT (clotting time) R (reaction time)
Normal (EXTEM)= 42–74 s Normal (citrate/
kaolin)= 3–8minNormal (INTEM)= 137–246 s
Clot formation/
kinetics (20mm
amplitude)
CFT (clot formation time) K (kinetics)
Normal (EXTEM)= 46–148 s Normal
(citrate/kaolin)= 1–3minNormal (INTEM)= 40–100 s
Clot
strengthening
(angle of clot
formation)
Alfa angle (slope of tangent at
2mm amplitude)
Alfa angle (slope
between r and k points)
Normal (EXTEM)= 63–81° Normal
(citrate/kaolin)= 55–78°Normal (INTEM)= 71–82°
Amplitude/
maximal firmness
MCF (maximum clot firmness) MA (maximal amplitude)
Normal (EXTEM)= 49–71mm Normal (citrate/
kaolin)= 51–69mmNormal (INTEM)= 52–72mm
Normal (FIBTEM)= 9–25mm
A5, A10, etc. – amplitudes at
dedicated time-points
predicting the final clot firmness
Lysis LI30, LI60, ML CL30, CL60, CL
the consumption and dilution-limited crystalloid infusions and
the use of massive transfusion protocols with 1:1:1 proportion
of fresh-frozen plasma, platelet concentrates and erythrocytes
(sometimes termed “hemostatic” or “whole blood” resuscitation)
were proposed (11). In more than 30 studies (mostly retrospective
or observational), this approach was associated with improved
survival (even after the survival bias being acknowledged) (12,
13), and it is currently widely adopted in North America (14).
However, in recently published observations, even this aggressive
high ratio of blood component therapy (1:1 fresh-frozen plasma
to packed red blood cells) was unable to reverse the TIC (15,
16). Moreover, massive transfusion protocols expose patients to
risks associated with transfusion, including immune reactions or
transfusion-related acute lung injury (17).
In the recent years, several important findings were published
altering the simplistic “consumption/dilution” view on TIC (18,
19). Rourke et al. (20) described the association of TIC with
low levels of fibrinogen hypothesizing that the consumption of
fibrinogen occurs in much more faster pace than that of other
factors in trauma bleeding. Actually, only limited number of
CT
R
CFT
K
A10 MCF
MA
α
α
ML
CL
FIGURE 2 | The typical tracings of ROTEM® (upper panel) and TEG®
devices (lower panel) with the most prominent parameters of both
methods with the comparison (see also Table 2).
trauma patients (about 20%) experience severe deficiency of
clotting factors, namely factor V (21). Few studies verified this
finding of trauma-associated hypofibrinogenemia (22, 23). Faster
turnaround of fibrinogen associated with hyperfibrinolysis is
another reason for hypofibrinogenemia in some patients. Direct
tissue trauma, organ hypoperfusion (24), endothelial disruption
(25), or protein C activation was found to contribute for increased
plasmin formation and fibrin degradation (26–28). The real pro-
portion of patients experiencing trauma-associated hyperfibri-
nolysis is unknown. Severe hyperfibrinolysis defined as more
than 15% lysis observed within 30min after reaching maximal
clot amplitude was described in more than 5% of patients and
associated with 80% fatality rate (Table 3). But even fibrinolysis
of much milder extent (3% lysis in 30min derived from TEG®
measurement) was associated with increased transfusion needs
and higher mortality (29). If the survival benefit of antifibrinolyt-
ics is observed in the recent large multi-centric CRASH-2 trial,
one may hypothesize that hyperfibrinolysis occurs much more
frequently than previously thought. These findings promoted the
use of fibrinogen concentrates as well as the use of antifibrinolytic
agents in routine praxis.
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TABLE 3 | The occurrence of trauma-associated hyperfibrinolysis.
Population Hyperfibrinolysis incidence Mortality
Levrat (30) 87 6% 100%
Caroll (31) 161 2.5% 67%
Schochl (32) Not available 33 pts 88%
Tauber (33) 334 6.8% 85.7%
Kashuk (34) 61 18% 64%
Global population 643 6.7% 80.9%
Viscoelastic methods helped to delineate these most prominent
features of what we call nowadays acute trauma coagulopathy.
Both low fibrinogen levels and fibrinolysis are diagnosable with
the use of VEM-specific tests in real time. Hence, these meth-
ods can substantially contribute to the management of acute
trauma-associated bleeding (35). Several goal-oriented protocols
are available in literature helping to couple the VEM test results
with proper treatment (36) (see also Figure 3 for authors’ own
institution protocol). The early administration of tranexamic acid
(sometimes even in the prehospital setting) and goal-oriented
fibrinogen or supplementation of coagulation factors decreased
the use of blood products, namely fresh-frozen plasma. The so-
called plasma-free approach, in which factor concentrates are
only used for coagulation management, has evolved in some
institutions in the extreme. This approach may further decrease
the risks of blood products therapy. However, the goal-oriented
coagulation management and plasma-free approach in trauma
victims are still a matter of debate. Some observation studies have
demonstrated the significant drop in use of blood products (37–
40), but no prospective randomized trial compared the plasma-
free VEM-goal-oriented treatment with the massive transfusion
protocols (41). Nevertheless, in view of this evidence, the use of
VEM as a guide of bleeding management in trauma victims was
upgraded to “1C” in the most recent European Trauma Treatment
Guidelines (42).
VEM for Perioperative Care
Unlike the use of VEM in acute trauma care, the utility of
these methods for managing acute bleeding in cardiac or hep-
atic surgery is much more established in the literature. Both
named as clinical scenarios are often coupled with the coagu-
lopathy of complex origin, which may be very difficult to assess
using standard laboratory test. In patients undergoing cardiac
bypass surgery, several factors can impede blood clotting mak-
ing the management very demanding: the exposition of blood
components to the extracorporeal circuit, possible coagulation
factors dilution and/or consumption, use of heparin or other
anticoagulants, and finally chronic antiplatelet mediation (43).
VEM assays able to eliminate heparin influence (HEPTEM or
Kaolin/HeparinaseTEG)may help to distinguish between residual
heparinization and other sources of bleeding. In a similar way,
blood clotting in patients undergoing orthotopic liver transplan-
tation or large liver resection may be altered by chronic liver
disease with the malproduction of pro- and anti-coagulant factors
not only by major blood loss and postoperative acute liver fail-
ure but also by the fibrinolytic shutdown and procoagulant state
(44). VEM devices are not able to elucidate all of these problems
(see Limitations of Contemporary VEM Analyses) but, unlike
standard methods, may better assess the dynamic balance of the
secondary hemostasis and lysis (45).
Several studies were published in recent years using TEG® or
ROTEM® driven protocols of care especially in cardiosurgical
procedures. Wikkelsoe’s Cochrane review group (46) managed
to identify nine randomized trials (eight cardiosurgical and one
orthotopic liver transplantation) showing the overall benefit of
VEM-managed patients in surrogate markers like bleeding or
number of used blood products. More recently, Weber et al. (47)
showed significant decrease not only in the use of blood products
or bleeding risk but also in 6-month mortality and demonstrated
overall economic benefit. The National Institute for Health and
Care Excellence recommends in its recent guidelines that TEG®
and ROTEM® devices may be used to help monitor blood clotting
during and after the heart surgery (48).
There is a sparse evidence of using the VEM for other proce-
dures associated with the risk of major bleeding (i.e., obstetric).
During pregnancy, the coagulation system changes in a very
complex way meeting its peak at the moment of delivery. Unlike
other situations, the postpartum hemorrhage is often associated
with both increased (and disseminated) thrombi generation and
bleeding due to the consumption of coagulation factors and the
fibrin lysis. The use of VEM can help significantly in the nonsurgi-
cal management of severe postpartum hemorrhage (49); however,
this proposal is built on assumptions based on acute trauma or
cardiosurgical care.
Perspectives of VEM Analysis
The utility of VEM for management of bleeding has significantly
expanded the knowledge and also the use of these devices among
the anesthesiologists and the critical care physicians. However, it
seems that the applicability reaches much further than the initial
trauma or perioperative bleeding risk assessment. Several authors
have studied the utility of VEM for the assessment of sepsis-
associated coagulopathy (50, 51). The association of VEM diag-
nosed hypocoagulabilitywith the severity of disease, andmortality
was evidenced in recent systematic review (52). However, having
only low number of relevant studies and rather complex nature
of sepsis-associated coagulopathy, possibly more data are needed
before the routine use of VEM for this indication.
In the recent years, several authors have demonstrated that
VEM are able to assess not only the hypocoagulable phenotype
but also the hypercoagulable phenotype, which develops as a
contra regulatorymechanism several hours or days after traumatic
or surgical injury (53). Hypercoagulability assessed using the
standard VEM variables (clotting time, initial angle, or maximal
firmness) was demonstrated to be associated with the rate of
thromboembolic events in the later course of illness (5, 54). Park
et al. (55) demonstrated that trauma patients with subsequent pul-
monary embolization had increased angle and amplitude of clot
formation within first 48 h as compared with the control group,
but no difference in standard coagulation tests was observed.
Recently,Müller et al. (56) usedVEM tests (total clot strength –G)
to separate patients withmultiple trauma into those having hypo-,
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TRAUMA INDUCED COAGULAPATHY
LOCAL TREATMENT GUIDELINE 
Trauma vicim with ISS > 16 (BE ≤ -6 mmol/l, lactate > 2 mmol/l)
General treatment measures:
• Normalize body temperature
• pH > 7,2;  Ca2+ > 1 mmol/l
• Hematocrit > 24%
TRANEXAMIC ACID:
• Up to 3 hour a"er insult
• 1g i.v. bolus
• 1g i.v. connuous for 8 hours
Start ROTEM (EXTEM, FIBTEM) analysis
(make bed-side blood gas analysis + standard laboratory for blood components and coagula!on incl. ﬁbrinogen level)
EXTEM CT > 80s 
PCC 20 U/kg 
or FFP 30 ml/kg
FIBTEM A10 ≤ 7mm 
FIBRINOGEN
A10 (0-3mm) = 6-8 g
A10 (4-7 mm) = 4-6 g
EXTEM A10 ≤ 40mm
and FIBTEM A10 > 12mm 
PLATELETS ≤ 105/µl
PLATELETS 
aim PLATELETS > 105/µl
EXTEM A10 ≤ 30mm
= SEVERE CLOTTING DISORDER
ALL PREVIOUS
(PCC/FFP + FBG + PLT)
SUSPICION/KNOWN USE: 
ANTIPLATELET meds
Consider administering PLATELETs even under
normal PLT counts and ROTEM tests
NEW PERORAL 
ANTICOAGULANTS
Consider increasing the PCC to 30-50 U/kg 
when pathological ROTEM tests
FIGURE 3 | The protocol of acute traumatic coagulopathy of the authors’ institution (English translation).
normo-, and hypercoagulable states. A hypercoagulable profile
(G  11.7 dynes cm 2) was observed in 10% of trauma popu-
lation. Using novel parameters obtainable from the VEM curve,
Gonzalez et al. (8) were able to separate the platelet and enzymatic
hypercoagulability. This new insight enabled by VEM to monitor
the hypercoagulable phenotype may significantly affect the way
how we would possibly prescribe thromboprophylaxis for the
years to come. It was concluded by Patel (57) that most throm-
boembolic events occurred not only because the thromboprophy-
laxis was not prescribed, but also because it was not effective. The
use of VEM not only for goal-directed bleeding management but
also for the thromboprophylaxis seems to be alluring; however,
nowadays we are lacking data for such approach. Definitely, before
the routine application of VEM for thromboprophylaxis man-
agement, more specific tests for the assessment of anticoagulants
use and their effectivity (see Limitations of Contemporary VEM
Analyses) and possibly also new variables are needed.
Limitations of Contemporary VEM Analyses
The coagulation assessment of VEM using full blood is much
more complex than the standard laboratory tests. Unlike standard
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methods performed under optimal conditions (often 37°C), most
VEM devices are able to adapt to the actual body temperature.
However, some aspects of in vivo clotting are immeasurable by
this method. First, most of contemporary practiced VEM assays
use decalcinated blood for practical reason; hence, calcium levels
have to be tested separately. The historical TEG method used
native blood, where the NATEM also enables to alleviate this, but
the use of native (calcinated) blood cannot account for the time
between clotting commencement (blood taking) and initiation of
the exam. More importantly, all the VEM tests can only assess the
secondary hemostasis. Given the cellular theory of hemostasis, the
influence of endothelium–platelet interaction (primary hemosta-
sis) cannot be examined. Because most of the generally used
antiaggregantmedication influences primary hemostasis either by
affecting the cyclooxygenase-1 (aspirin or other nonsteroidal anti-
inflammatory drugs) or by blocking the adenosine-di-phosphate
receptor (clopidogrel and similar substances), current VEM tests
are blind to their effect. The ROTEM platelet® platform intro-
duced recently combines the VEM with two-channel multiplate
aggregometry enabling to assess the effect of common antiplatelet
medication. Similarly, the “Platelet Mapping” TEG modality uses
ADP+ arachidonic acid to stimulate and analyze platelet aggre-
gation. Use and effect of such POCT for clinical routine were not
tested yet.
Furthermore, the influence of new anticoagulants (direct
thrombin inhibitors – dabigatran, argatroban; direct factor Xa
inhibitors – rivaroxaban, apixaban) as well as of low-molecular
weight heparins (specifically anti-Xa activity) on VEM assays is
not described well in the literature. All these anticoagulants affect
the secondary hemostasis, which should make them evaluable by
the VEM tests. However, Schaden et al. (10) demonstrated lim-
ited correlation between clotting time values and anti-Xa activity
measured by classical INTEM test, which improved when specific
tests (PiCT – prothrombinase-induced clotting or LowTF – low-
tissue factor activated modification) were applied. Eller et al. (58)
demonstrated that ROTEM® assessed clotting time was able to
assess the in vitro therapeutic concentrations of most of the tested
novel per oral anticoagulants (but fondaparinux). However, the
prolongation of clotting time is a very unspecific marker that
may delay time to proper treatment in case of need. Ecarin mod-
ification of ROTEM tests was used by Schaden (9) to improve
the significance toward argatroban recently. Whether these novel
modifications will help in elucidating the effect of other novel
anticoagulants is still unresolved. Moreover, these more specific
tests are not clinically available and therefore not routinely per-
formed. This makes the assessment of anticoagulation via VEM
tests elusive.
Conclusion
Viscoelastic methods of coagulation assessment offer time-
relevant information about the function of secondary hemostasis.
Based on their assessment, a goal-oriented treatment of trauma-
associated coagulopathy is feasible decreasing the exposition to
blood products and associated risks. In patients undergoing car-
diac or liver surgery, the use of VEM was found to improve
care, and similar findings may be also expected from the other
major bleeding scenarios. The use of VEM in other situations
(i.e., septic coagulopathy, hypercoagulation assessment) might be
enabled in the near future. But as with any other monitoring
tools, it is not the device to blame or honor. The VEM can affect
patients’ outcomes only when we will use them and find treat-
ments based on the derived variables affecting patients’ outcome,
which should be the agenda of our research activities for the next
few years.
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